Cargando…

T-cell lymphoma secondary to checkpoint inhibitor therapy

BACKGROUND: Murine model suggests programmed cell death-1 (PD-1), an immune checkpoint not only plays role in tumor escape but is also a tumor suppressor for T-cells. But until, no reports of secondary T-cell lymphoma postuse of immune checkpoint inhibitors (ICIs) has been reported. Herein, we prese...

Descripción completa

Detalles Bibliográficos
Autores principales:	Anand, Kartik, Ensor, Joe, Pingali, Sai Ravi, Hwu, Patrick, Duvic, Madeleine, Chiang, Stephen, Miranda, Roberto, Zu, Youli, Iyer, Swaminathan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2020
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7057430/ https://www.ncbi.nlm.nih.gov/pubmed/32114498 http://dx.doi.org/10.1136/jitc-2019-000104

Ejemplares similares

Mycobacterial infections due to PD-1 and PD-L1 checkpoint inhibitors
por: Anand, Kartik, et al.
Publicado: (2020)

Complete Response to R-EPOCH in Primary Cardiac Lymphoma
por: Anand, Kartik, et al.
Publicado: (2019)

G6PD deficiency and severity of COVID19 pneumonia and acute respiratory distress syndrome: tip of the iceberg?
por: Youssef, Jihad G., et al.
Publicado: (2021)

Cryptococcal meningoencephalitis in patients with mantle cell lymphoma on ibrutinib
por: Sun, Kai, et al.
Publicado: (2018)

Use of PEG-asparaginase in a case of Hepatosplenic γδ T-cell lymphoma with long-term remission after stem cell transplantation
por: Sun, Kai, et al.
Publicado: (2018)

Use of PEG-asparaginase in monomorphic epitheliotropic intestinal T-cell lymphoma, a disease with diagnostic and therapeutic challenges
por: Gentille, Cesar, et al.
Publicado: (2017)

Macrophage Activation Syndrome Secondary to Underlying Sarcoidosis
por: Kasparian, Saro, et al.
Publicado: (2019)

Angioimmunoblastic T-cell lymphoma associated with immune checkpoint inhibitor treatment
por: Duke, Taylor C., et al.
Publicado: (2020)

Radiation therapy in primary mediastinal large B‐cell lymphoma treated with DA‐R‐EPOCH
por: Gentille, Cesar, et al.
Publicado: (2020)

Primary diffuse large B-cell lymphoma of the uterus: A SEER database analysis
por: Ensor, Allyne M., et al.
Publicado: (2021)

Cardiotoxicity Associated with Anti-CD19 Chimeric Antigen Receptor T-Cell (CAR-T) Therapy: Recognition, Risk Factors, and Management
por: Burns, Ethan A., et al.
Publicado: (2021)

Update on the treatment of cutaneous T-cell lymphoma (CTCL): Focus on vorinostat
por: Duvic, Madeleine, et al.
Publicado: (2007)

A novel role of lysophosphatidic acid (LPA) in human myeloma resistance to proteasome inhibitors
por: Su, Pan, et al.
Publicado: (2022)

Immune-Checkpoint Inhibitors in B-Cell Lymphoma
por: Armengol, Marc, et al.
Publicado: (2021)

The development of T-cell malignancies in patients with pre-existing myeloproliferative neoplasms: a report of three cases
por: Burns, Ethan A, et al.
Publicado: (2020)

Aptamer technology: a new approach to treat lymphoma?
por: Zu, Youli
Publicado: (2020)

New B-cell Lymphomas in the Setting of a Previous Rare Breast Implant–Associated B-cell Lymphoma
por: Messer, Alison, et al.
Publicado: (2016)

Osimertinib-Induced Cardiotoxicity: A Retrospective Review of the FDA Adverse Events Reporting System (FAERS)
por: Anand, Kartik, et al.
Publicado: (2019)

Understanding itch in cutaneous T-cell lymphoma: Exploring the impact of comorbidities, treatment regimens, and racial differences on quality of life
por: Joshi, Tejas P., et al.
Publicado: (2022)

Unmasking a T cell lymphoma: Folliculotropic mycosis fungoides with a gamma-delta phenotype
por: Tran, Jessica, et al.
Publicado: (2020)

Recurrent small bowel obstruction caused by Burkitt lymphoma in an elderly man: a case report and review of the literature
por: Kasparian, Saro, et al.
Publicado: (2020)

Immune Checkpoint Inhibitors to Treat Malignant Lymphomas
por: Witkowska, Magdalena, et al.
Publicado: (2018)

Immune Checkpoint Inhibitors in Peripheral T-Cell Lymphoma
por: Chen, Xi, et al.
Publicado: (2022)

Immune checkpoint inhibitors in lymphoma: challenges and opportunities
por: Hatic, Haris, et al.
Publicado: (2021)

Primary cutaneous anaplastic large-cell lymphoma: Complete remission for 13 years after denileukin diftitox
por: Lewis, Daniel J., et al.
Publicado: (2017)

Aptamer-Equipped Protamine Nanomedicine for Precision Lymphoma Therapy
por: Zeng, Zihua, et al.
Publicado: (2020)

Use of ifosfamide, carboplatin and etoposide in combination with brentuximab vedotin or romidepsin based on CD30 positivity in relapsed/refractory peripheral T‐cell lymphoma
por: Gentille, Cesar, et al.
Publicado: (2022)

Pulmonary Complications Secondary to Immune Checkpoint Inhibitors
por: Albitar, Hasan Ahmad Hasan, et al.
Publicado: (2020)

Safety of Concurrent Radiation Therapy With Brentuximab Vedotin in the Treatment of Lymphoma
por: Wu, Susan Y., et al.
Publicado: (2023)

Pre-clinical efficacy of combined therapy with novel β-catenin antagonist BC2059 and histone deacetylase inhibitor against AML cells
por: Fiskus, Warren, et al.
Publicado: (2014)

The Role of Immune Checkpoint Inhibitors in Classical Hodgkin Lymphoma
por: Meti, Nicholas, et al.
Publicado: (2018)

Immune checkpoint inhibitors in malignant lymphoma: Advances and perspectives
por: Lin, Ningjing, et al.
Publicado: (2020)

Checkpoint Inhibitors in Relapsed/Refractory Classical Hodgkin Lymphoma
por: Tarekegn, Kidist, et al.
Publicado: (2021)

A Review of Hodgkin Lymphoma in the Era of Checkpoint Inhibitors
por: Schimmoeller, Christopher J, et al.
Publicado: (2023)

Hepatitis B Virus Reactivation in Cancer Patients Treated With Immune Checkpoint Inhibitors
por: Burns, Ethan A., et al.
Publicado: (2021)

Hypokalemic Paralysis Secondary to Immune Checkpoint Inhibitor Therapy
por: Balakrishna, Pragathi, et al.
Publicado: (2017)

Hemophagocytic Lymphohistiocytosis Secondary to Immune Checkpoint Inhibitor Therapy
por: Rajapakse, Pramuditha, et al.
Publicado: (2022)

An unusual case of cytotoxic peripheral T-cell lymphoma
por: Wang, Casey, et al.
Publicado: (2015)

Targeted Therapies and Immune Checkpoint Inhibitors in Primary CNS Lymphoma
por: Wirsching, Hans-Georg, et al.
Publicado: (2021)

Updates in the Role of Checkpoint Inhibitor Immunotherapy in Classical Hodgkin’s Lymphoma
por: Nakhoda, Shazia, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_kvljijk5tknhngcjm9r8tj07ib